{"transactions":[{"id":711232,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":false,"shares":25,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":33257,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":25},"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711231,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":false,"shares":1015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":33282,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":1015},"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711230,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-09","kind":"sale","planned":true,"acquired":false,"shares":25,"price":16,"value":400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":135202,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711229,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-09","kind":"exercise","planned":true,"acquired":true,"shares":25,"price":1.01,"value":25.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":135227,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711228,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":1015,"price":16,"value":16240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":135202,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":711227,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-10T21:20:40.000Z","date":"2026-07-08","kind":"exercise","planned":true,"acquired":true,"shares":1015,"price":1.01,"value":1025.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":136217,"source":{"system":"sec-edgar","filing":"0001628280-26-047909","document":"wk-form4_1783718438.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047909/wk-form4_1783718438.xml","form_type":"4"}},{"id":718300,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":4183,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock options are fully vested and exercisable."}],"balance_after":34297,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":4183},"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718299,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T21:47:14.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":28826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock options are fully vested and exercisable."}],"balance_after":38480,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":28826},"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718298,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":2501,"price":16.2369,"value":40608.4869,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.40, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":135202,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718297,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":5852,"price":15.6667,"value":91681.5284,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.15  to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":137703,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718296,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":4183,"price":1.01,"value":4224.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":143555,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718295,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":28826,"price":16.0372,"value":462288.3272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.35, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":139372,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":718294,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-07-02T21:47:14.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":28826,"price":1.01,"value":29114.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":168198,"source":{"system":"sec-edgar","filing":"0001628280-26-047058","document":"wk-form4_1783028831.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026047058/wk-form4_1783028831.xml","form_type":"4"}},{"id":757199,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-06-01T22:08:39.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":13.1564,"value":54862.188,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.995  to $13.360, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":139372,"source":{"system":"sec-edgar","filing":"0001628280-26-039641","document":"wk-form4_1780351717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026039641/wk-form4_1780351717.xml","form_type":"4"}},{"id":795814,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-05-01T21:42:37.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":300,"price":13.84,"value":4152.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.79 to $13.86, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":143542,"source":{"system":"sec-edgar","filing":"0001628280-26-029435","document":"wk-form4_1777671753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026029435/wk-form4_1777671753.xml","form_type":"4"}},{"id":795813,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-05-01T21:42:37.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":3870,"price":13.06,"value":50542.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69  to $13.57, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":143842,"source":{"system":"sec-edgar","filing":"0001628280-26-029435","document":"wk-form4_1777671753.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026029435/wk-form4_1777671753.xml","form_type":"4"}},{"id":814528,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-04-06T21:43:32.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":13.4326,"value":56013.942,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.60, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":147712,"source":{"system":"sec-edgar","filing":"0001628280-26-023949","document":"wk-form4_1775511809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000162828026023949/wk-form4_1775511809.xml","form_type":"4"}},{"id":874471,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-03-02T23:30:02.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":15.0084,"value":62585.028,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.60 to $15.41, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":151882,"source":{"system":"sec-edgar","filing":"0001437749-26-006422","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926006422/rdgdoc.xml","form_type":"4"}},{"id":879847,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":false,"shares":3824,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":67306,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":3824},"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879846,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":4300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock options are fully vested and exercisable."}],"balance_after":71130,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":4300},"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879845,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":3824,"price":16.0115,"value":61227.976,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.05, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879844,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-25","kind":"exercise","planned":true,"acquired":true,"shares":3824,"price":1.01,"value":3862.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":159876,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879843,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":4300,"price":16.0316,"value":68935.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.15, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":879842,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-26T21:39:06.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":4300,"price":1.01,"value":4343.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":160352,"source":{"system":"sec-edgar","filing":"0001437749-26-005889","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926005889/rdgdoc.xml","form_type":"4"}},{"id":890846,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T21:05:35.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":75430,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001437749-26-004912","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004912/rdgdoc.xml","form_type":"4"}},{"id":890845,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-20T21:05:35.000Z","date":"2026-02-19","kind":"sale","planned":true,"acquired":false,"shares":100,"price":16,"value":1600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-004912","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004912/rdgdoc.xml","form_type":"4"}},{"id":890844,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-20T21:05:35.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":1.01,"value":101.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156152,"source":{"system":"sec-edgar","filing":"0001437749-26-004912","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004912/rdgdoc.xml","form_type":"4"}},{"id":905366,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-13T21:26:06.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock options are fully vested and exercisable."}],"balance_after":75530,"derivative":{"exercise_price":1.01,"expiration_date":"2030-02-24","underlying":"Class A Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001437749-26-004122","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004122/rdgdoc.xml","form_type":"4"}},{"id":905365,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:26:06.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":400,"price":16,"value":6400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-004122","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004122/rdgdoc.xml","form_type":"4"}},{"id":905364,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-13T21:26:06.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":1.01,"value":404.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."}],"balance_after":156452,"source":{"system":"sec-edgar","filing":"0001437749-26-004122","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926004122/rdgdoc.xml","form_type":"4"}},{"id":917845,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-05T21:24:59.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":1170,"price":15.2451,"value":17836.767,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $15.45, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":156052,"source":{"system":"sec-edgar","filing":"0001437749-26-003212","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926003212/rdgdoc.xml","form_type":"4"}},{"id":917844,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-02-05T21:24:59.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":14.8229,"value":44468.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $15.08, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":157222,"source":{"system":"sec-edgar","filing":"0001437749-26-003212","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926003212/rdgdoc.xml","form_type":"4"}},{"id":927107,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:54:35.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's spouse's continuous service."}],"balance_after":6500,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001437749-26-002576","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926002576/rdgdoc.xml","form_type":"4"}},{"id":927106,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-30T21:54:35.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"). The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service."}],"balance_after":160000,"derivative":{"exercise_price":14.26,"expiration_date":"2036-01-29","underlying":"Class A Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001437749-26-002576","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926002576/rdgdoc.xml","form_type":"4"}},{"id":947035,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-01-06T21:16:27.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":500,"price":11.1298,"value":5564.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.34, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":160222,"source":{"system":"sec-edgar","filing":"0001437749-26-000616","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926000616/rdgdoc.xml","form_type":"4"}},{"id":947034,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2026-01-06T21:16:27.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":3670,"price":10.3483,"value":37978.261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.000 to $10.955, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":160722,"source":{"system":"sec-edgar","filing":"0001437749-26-000616","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774926000616/rdgdoc.xml","form_type":"4"}},{"id":957255,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2025-12-30T21:10:34.000Z","date":"2025-12-23","kind":"sale","planned":true,"acquired":false,"shares":4170,"price":12.2324,"value":51009.108,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.38, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":164392,"source":{"system":"sec-edgar","filing":"0001437749-25-038936","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774925038936/rdgdoc.xml","form_type":"4"}},{"id":1289685,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:38:59.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service."}],"balance_after":3700,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":3700},"source":{"system":"sec-edgar","filing":"0001437749-25-002431","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774925002431/rdgdoc.xml","form_type":"4"}},{"id":1289684,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-31T21:38:59.000Z","date":"2025-01-31","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"). 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":110000,"derivative":{"exercise_price":9.79,"expiration_date":"2035-01-30","underlying":"Class A Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001437749-25-002431","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774925002431/rdgdoc.xml","form_type":"4"}},{"id":1349595,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2024-11-27T22:06:15.000Z","date":"2024-11-25","kind":"sale","planned":true,"acquired":false,"shares":1010,"price":16.0172,"value":16177.372,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.14, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":168562,"source":{"system":"sec-edgar","filing":"0001437749-24-036349","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774924036349/rdgdoc.xml","form_type":"4"}},{"id":1357393,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2024-11-20T22:07:24.000Z","date":"2024-11-18","kind":"sale","planned":true,"acquired":false,"shares":99,"price":17.05,"value":1687.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024."}],"balance_after":169572,"source":{"system":"sec-edgar","filing":"0001437749-24-035887","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774924035887/rdgdoc.xml","form_type":"4"}},{"id":1357392,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Class A Common Stock","published_at":"2024-11-20T22:07:24.000Z","date":"2024-11-18","kind":"sale","planned":true,"acquired":false,"shares":6091,"price":16.3738,"value":99732.8158,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 19, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.03 to $17.02, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":169671,"source":{"system":"sec-edgar","filing":"0001437749-24-035887","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774924035887/rdgdoc.xml","form_type":"4"}},{"id":1499297,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:58:18.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":3700,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options granted under the Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service."}],"balance_after":3700,"derivative":{"exercise_price":15.76,"expiration_date":"2034-05-23","underlying":"Class A Common Stock","underlying_shares":3700},"source":{"system":"sec-edgar","filing":"0001437749-24-018624","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774924018624/rdgdoc.xml","form_type":"4"}},{"id":1499296,"issuer":{"id":5311,"kind":"organization","name":"Contineum Therapeutics, Inc.","symbol":"CTNM"},"owners":[{"id":31004,"kind":"person","name":"Lorrain Daniel S.","position":1,"cik":"0001861550","reported_name":"Lorrain Daniel S.","relationship":{"officer":true,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-29T21:58:18.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options granted under the Issuer's 2024 Equity Incentive Plan (the \"Plan\"). 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service."}],"balance_after":100000,"derivative":{"exercise_price":15.76,"expiration_date":"2034-05-23","underlying":"Class A Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001437749-24-018624","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861550/000143774924018624/rdgdoc.xml","form_type":"4"}}]}